After nearly seven years at Novartis and more than four years as a member of the ECN, Ms. Tschudin will pursue her next chapter of leadership outside of Novartis Dr. Horber to drive next phase of international growth, shape commercial strategy, and continue Novartis leadership in reimagining medicines for patients around the world Basel, September 06, 2023 — Novartis today announced that Marie-France Tschudin, President, Innovative Medicines International and Chief Commercial Officer, has decided to leave the company and will step down from the Executive Committee of Novartis (ECN), effective September 15, after nearly seven years of commercial leadership at Novartis.

经过诺华近七年的工作和ECN成员四年多的工作，Tschudin女士将在诺华以外的领域继续领导下一章-霍伯博士推动下一阶段的国际增长，塑造商业战略，并继续诺华领导在世界各地为患者重新设药巴塞尔，06年9月，2023年-诺华今天宣布，创新药物国际总裁兼首席商业官Marie-France Tschudin已决定离开该公司，并将于近7年后于9月15日生效，从诺华执行委员会（ECN）辞职诺华的商业领导。

Patrick Horber, M.D., currently Senior Vice President and President, Immunology at AbbVie has been appointed as President, International, effective later this year, reporting to Vas Narasimhan, M.D., CEO of Novartis. Dr. Horber will become a member of the ECN. Mukul Mehta, Chief Financial Officer, International, will lead the unit ad-interim until Dr.

Patrick Horber，医学博士，现任AbbVie免疫学高级副总裁兼总裁，已被任命为国际总裁，今年晚些时候生效，向诺华首席执行官Vas Narasimhan报告。Horber博士将成为ECN的成员。Mukul Mehta，首席财务官，国际，将领导该单位的临时工作，直到博士。

Horber assumes the role. “I leave Novartis with a strong sense of pride and accomplishment in how we have delivered on our purpose,” Marie-France Tschudin said. “My deep esteem and gratitude go to the Novartis colleagues around the globe for their trust, hard work, and relentless efforts in getting patients the treatments they need, faster.” Vas Narasimhan said: “I want to thank Marie-France for her extraordinary leadership during her nearly seven years at Novartis.

霍伯担任这个角色。Marie-France Tschudin说：“我让诺华对我们如何实现目标感到自豪和成就。“我深表尊重和感激地请全球诺华同事，感谢他们的信任，辛勤工作以及不懈努力，让患者更快地获得所需的治疗。”Vas Narasimhan说：“我要感谢Marie France在诺华公司近七年的卓越领导。

She has been integral to reimagining our commercial model and the way we deliver innovative medicines to patients around the world. Marie-France has led her teams to remarkable growth. The impact she has had on our business, on our people, and on patients around the world will be long-lasting. I.

她一直是重新设计我们的商业模式以及我们向世界各地的患者提供创新药物的方式不可或缺的一部分。Marie France领导她的团队取得了显着增长。她对我们的业务，对我们的人民以及世界各地的患者所产生的影响将是持久的。一世。